Nicolas Williet PhD
University Institute of Cancerology and Hematology of Saint-Etienne (ICHUSE), France · France
Editorial leadership for International Journal of Negative Results ISSN 2641-9181
Research interests
- Pancreatic Cancer; Interventional Endoscopy; Ultrasound Echoendoscopy
Biography
Nicolas Williet is affiliated with the University Institute of Cancerology and Hematology of Saint-Etienne (ICHUSE), France, where his research focuses on pancreatic cancer, interventional endoscopy, and ultrasound echoendoscopy. His work spans inflammatory bowel diseases, including studies on cytomegalovirus in ulcerative colitis, fecal calprotectin and infliximab trough levels for predicting clinical relapse in Crohn's disease, and patient-reported outcomes in clinical trials. He has also contributed to research on hepatocellular carcinoma treatment and colorectal adenoma biomarkers. His most-cited publication, "Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial" (2021), has received 61 citations, and he has authored over 17 indexed publications.
Selected publications
- Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial 2021 cited 61×
- Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study 2019 cited 47×
- Gemcitabine and Paclitaxel Versus Gemcitabine Alone After 5-Fluorouracil, Oxaliplatin, and Irinotecan in Metastatic Pancreatic Adenocarcinoma: A Randomized Phase III PRODIGE 65-UCGI 36-GEMPAX UNICANCER Study 2024 cited 31×
- Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: update of the AGEO cohort 2021 cited 25×
- The Simplified Magnetic Resonance Index of Activity (MARIA) for Crohn’s Disease Is Strongly Correlated With the MARIA and Clermont Score: An External Validation 2020 cited 18×
- Ampullary tumors: French Intergroup Clinical Practice Guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, ACHBT, AFC, SFRO, RENAPE, SNFCP, AFEF, SFP, SFR) 2024 cited 14×
Ranked by citation impact (Crossref) where available, newest otherwise · verified via ORCID.
Considering IJNR for your work?
This journal is guided by Nicolas Williet (University Institute of Cancerology and Hematology of Saint-Etienne (ICHUSE), France) and a peer-review board of practising researchers. Open access, author-retained copyright (CC BY), and a clear editorial process.